Invitation-Immunovaccine Inc. Investor Reception
HALIFAX, NOVA SCOTIA -- (MARKET WIRE) -- 12/02/10 -- Immunovaccine Inc.'s (TSX VENTURE: IMV) management team invites members of the financial community to an Investor Reception on December 14, 2010 at 5:30 PM Atlantic Time at the Halifax Marriott Harbourfront Hotel. At this event Dr. Randal Chase, Immunovaccine President and CEO, will provide an update on the company's vaccine product pipeline and plans for 2011.
For event details and to confirm your attendance please contact Danielle Evans by email at [email protected] no later than December 10, 2010.
For those unable to attend in person, the presentation segment of the event will be available via conference call and audio webcast.
The conference call "listen-only mode" will be available by dialing 1-888-676-3321, access code: 5910952#. The presentation will begin at approximately 5:45 PM Atlantic time. A replay of the presentation will be available via audio webcast on Immunovaccine's investor webpage at: www.imvaccine.com/investors.php at 9:00 AM Atlantic time on December 15, 2010 until 5:00 PM Atlantic time on December 22, 2010.
About Immunovaccine Inc.
Immunovaccine Inc. (TSX VENTURE: IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax vaccine delivery technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. www.imvaccine.com
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Immunovaccine Inc. Jennifer Ayotte Communications 902-492-1819 [email protected] www.imvaccine.com
Released December 2, 2010